顶部联系方式

Time of issue:2018-03-12 00:00:00

Have Any Questions?  Mabspace BiosciencesInfo@mabspacebio.com 迈博斯生物0512-86861701

搜索
迈博斯生物

语言切换

Time of issue:2019-11-21 00:00:00
这是描述信息

NEWS

>>
>>
Maibos Bio has launched a Phase 1 clinical trial of its second-generation PD-L1 antibody in the United States

Maibos Bio has launched a Phase 1 clinical trial of its second-generation PD-L1 antibody in the United States

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2019-11-28 14:48
  • Views:

(Summary description)Maibos Bio has launched a Phase 1 clinical trial of its second-generation PD-L1 antibody in the United States

On April 16, 2018, Suzhou, China, Maibos Biopharmaceutical Co., Ltd. announced that its P

Maibos Bio has launched a Phase 1 clinical trial of its second-generation PD-L1 antibody in the United States

(Summary description)Maibos Bio has launched a Phase 1 clinical trial of its second-generation PD-L1 antibody in the United States

On April 16, 2018, Suzhou, China, Maibos Biopharmaceutical Co., Ltd. announced that its P

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2019-11-28 14:48
  • Views:
Information

Maibos Bio has launched a Phase 1 clinical trial of its second-generation PD-L1 antibody in the United States

On April 16, 2018, Suzhou, China, Maibos Biopharmaceutical Co., Ltd. announced that its PD-L1 antibody MSB2311 completed the first dose of the world's first patient in Texas, USA on April 12, 2018. MSB2311 is the second-generation PD-L1 antibody developed by Maibos using its unique immune tolerance barrier breakthrough technology platform. It has a unique pH dependence on antigen binding, which is conducive to recycling in tumor tissues and enhances tumor penetration 

 

Wan Yuntao, vice president of clinical development at Maibos, said, "Efficient clinical operations teams and partners have enabled us to quickly conduct clinical research by Dr. Papadopoulos at the START Cancer Research Center less than two months after the US FDA approves the IND. The team completed the first patient dosing. We would also like to thank Dr. Adjei of the Mayo Clinic for his valuable input on clinical trial design. He will also lead two other well-known researchers at the Mayo Clinic to participate in this study. Of course , The efficiency and quality of our clinical operations are inseparable from the strong support of our CRO partners Syneos Healthcare and Q2 Solutions. "

 

This study, MSB2311-CSP-001, is the first phase of a clinical study of humanized anti-PD-L1 monoclonal antibody MSB2311 in advanced solid tumors, with increasing dose and openness. More detailed information can be found at www.clinicaltrials.gov (NCT03463473). Another Phase I clinical trial to be conducted in China is in the final review stage of the CFDA. It is planned to initially evaluate the antitumor efficacy of MSB2311 in an expanded cohort of multiple tumor types.

 

Qian Xueming, founder and CEO of Maibos said, "We are glad that the clinical trial of MSB2311 in patients with advanced cancer has officially started. We are very much looking forward to the superior efficacy of MSB2311 in the preclinical study compared with similar antibodies in the clinic. The benefit translates into more patients in the study. "

 

About Maibos Bio

 

Maibosi Biomedical (Suzhou) Co., Ltd. is a biotechnology company focusing on research and development of innovative antibody drugs. Headquartered in Suzhou, the company has complete antibody drug discovery and development facilities in the Suzhou Industrial Park BioBAY Industrial Park (BioBAY). With its unique immune tolerance barrier breakthrough technology, it has established more than 10 product lines focusing on tumor immunotherapy. For more information, please visit Maibos website: www.mabspacebio.com

 

Contact Maibos Bio

Kathy YUAN

kathy.yuan@mabspacebio.com

+ 86-512-67079200-8008

Scan the QR code to read on your phone

页脚关于我们

Time of issue:2019-11-23 00:00:00

页脚管道

Time of issue:2019-11-23 00:00:00

页脚新闻

Time of issue:2019-11-23 00:00:00

页脚人力资源

Time of issue:2019-11-23 00:00:00

页脚联系方式

Time of issue:2019-11-23 00:00:00

页脚版权

Time of issue:2019-11-23 00:00:00

Copyright © 2019 Mabspace Biosciences All rights reserved

页脚备案

Time of issue:2019-11-23 00:00:00